Q-omics provides the consensus-scored LINC00866 profile across patient tissues and cancer cell-line models. LINC00866 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, LINC00866 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, LINC00866 RNA expression shows 10,253 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight CESC, LUAD, and PCPG as cancer lineages where LINC00866 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00866 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00866 survival associations across molecular data types. LINC00866 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00866 RNA expression–survival associations across cancer types. High LINC00866 expression shows unfavorable associations in CESC, ACC, HNSC, MESO and LUSC, but favorable associations in UVM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for LINC00866 RNA expression.
This table summarizes LINC00866 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00866. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00866 shows higher tumor expression in LUAD, THCA, LIHC, KIRC, COAD and LUSC. The LUAD box plot shows higher LINC00866 RNA expression in tumor versus normal tissue (log2 FC = +0.666, t-test p < 0.001).
This table shows molecular features associated with LINC00866 in patient tissues and cancer cell lines. In patient samples, LINC00866 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set.
